(CIDRAP News) The nation's supply of pandemic vaccine has grown to 111 million doses, enough so that the US Centers for Disease Control and Prevention (CDC) is turning part of its attention toward boosting the percentage of adults who get vaccinated.
(CIDRAP News) – A study in Australia showed that one dose of H1N1 influenza vaccine, rather than the two doses recommended in the United States, was enough to generate a probably protective immune response in children younger than 9 years.
(CIDRAP News) Federal officials, along with representatives from four vaccine companies, appeared before two US House of Representatives committees today to answer questions about why the nation hasn't stretched scarce pandemic vaccine supply with adjuvants and if a more federally directed distribution system might help vaccine get to more high-risk patients.
(CIDRAP News) – The nation's first doses of the pandemic H1N1 vaccine were administered today, mainly to a limited group of healthcare workers and emergency medical service workers, while some physicians' offices fielded calls about when the vaccine would be more widely available.
(CIDRAP News) Preliminary clinical trial results suggest that pandemic H1N1 vaccines made by Novartis and CSL Ltd. will provide protection in adults with just one dose, raising hope for a less difficult immunization program than has been anticipated.
(CIDRAP News) – The US Food and Drug Administration (FDA) today approved a vaccine filling and packaging facility in Illinois owned by CSL Biotherapies, one of the five companies under contract to make novel H1N1 vaccines for the United States, the company announced.
(CIDRAP News) Federal officials today during a pandemic H1N1 planning update dialed back the number of novel flu vaccine doses they expect in October from 120 million to 45 million, listing several reasons for the smaller projection.
(CIDRAP News) The World Health Organization (WHO) said today that the fast-tracking of vaccines for pandemic H1N1 influenza won't compromise safety, while acknowledging that clinical data will be limited when the first doses are administered.